Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*

Abstract

B.H. reports fees from Janssen-Cilag (for advisory boards, educational grants, consultations, investigator initiative studies), AbbVie (for advisory boards, educational grants, consultations, investigator initiative studies), Novartis Pharma (for advisory boards, consultations, investigator initiative studies), UCB Pharma (for advisory boards, consultations), Leo Pharma (for consultations), Solenne B.V. (for investigator initiative studies), Celgene (for consultations and investigator initiative studies), Akari Therapeutics (for consultations and investigator initiative studies), Philips (for consultation), Roche (for consultation), Regeneron (for consultation) and Sanofi (for consultation); the fees were payed to the institution. E.P.P. has received honoraria from AbbVie, Amgen, Celgene, Janssen, Galderma, Novartis and Pfizer for participation as a speaker and for serving on advisory boards; E.P.P. also received investigator-initiated grants (paid to Erasmus MC) from AbbVie, AstraZeneca, Janssen and Pfizer.

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa

“…Drug survival and associated predictors have been studied for adalimumab and infliximab [ 49 ]. Adalimumab has a 12-month drug survival in HS of 56.3% and a 24-month survival of 30.5%.…”

Insights into the Pathogenesis of HS and Therapeutical Approaches

“…In a recent retrospective multicenter study, the overall drug survival of IFX was 58.3% after 12 and 48.6% after 24 months. Surgery during treatment significantly improved IFX drug survival [ 192 ]. A study investigated adjuvant biologic therapy (with either IFX or ustekinumab) after surgical radical resection of HS lesions.…”

Biologic survival in hidradenitis suppurativa: much done, more to do

“…One crucial step in the diagnostic workup is patch testing, which is the approach taken by Silverberg et al, in their article in this issue. 3 In a study population of over 1600 paediatric patients (age < 18 years), 237 patients (14Á5%) were identified as having hand eczema. Almost 50% of these patients had the ACD subtype, 37% had the AHE subtype and (only) 17% had the irritant subtype (of which more than two-thirds of cases were work related).…”

“…2 In this issue, Prens et al report real-world drug survival data for adalimumab and infliximab in HS. 3 Until now, long-term data on adalimumab therapy was only available from the 3year open label extension (OLE) of PIONEER I and II trials. This showed a sustained response of 52Á3% to week 168 using last observation carried forward analysis.…”

“…5 Hand dermatitis was significantly increased (27%) in adolescents (compared with 14Á5%). 3 Children and adolescents showed significantly lower reaction rates to fragrance mix, methyldibromo glutaronitrile, methylisothiazolinone and propolis (which can be considered 'cosmetic-related' allergens). Positive reactions to mercapto mix among children and to cobalt among adolescents were significantly more frequent.…”